Los Altos, California June 1st, 2004-- Silicom Ventures a Silicon
Valley
investment group, today announced the closing of second round of funding for
Spectros Corporation by Silicom Ventures angel members.
Spectros Corporation of Portola Valley (CA) develops and markets
advanced
detection and imaging systems that use light to locate trace amounts disease
to direct interventional therapies in the body in real-time, such as therapies
for ischemia or cancer.
"Spectros attracted great interest from Silicom members".
Said Gadi Behar
the Founder and Managing Director of Silicom Ventures. "Spectos' products,
being non- or minimally-invasive devices fulfill a need that has been unmet
so far. The timing has also been perfect, when investors are gaining
confidence and are willing to invest after a long drought."
This funding round is anticipated to propel Spectros through
FDA approval
and into clinical sales of the T-Stat Oximeter, a device that monitors in real-time
the lack
of adequate oxygen delivery, called ischemia.
ABOUT SILICOM VENTURES
Silicom Ventures
provides a conduit for technological innovation linking qualified,
experienced investors with entrepreneurs from around the globe. Our investment
members include a diverse group
of over 200 Angel and Venture Capital investors, high tech executives and corporate
sponsors. More about
Silicom Ventures please visit www.silicomventures.com
ABOUT SPECTROS CORPORATION
Develops and markets advanced
detection and imaging systems that use light to locate trace amounts disease
to direct interventional therapies in the body in real-time. More about Spectros
Corp. please visit www.spectros.com
Contact information:
Tal Behar
Executive Director
Silicom Ventures
1442 Fowler Ln.
Los Altos, CA 94024
tal@silicomventures.com